Mark J. Gergen
2020 - Poseida Therapeutics
In 2020, Mark J. Gergen earned a total compensation of $1.4M as Chief Executive Officer and President and former Chief Business Officer at Poseida Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $194,710 |
|---|---|
| Option Awards | $804,500 |
| Salary | $432,680 |
| Other | $9,102 |
| Total | $1,440,992 |
Gergen received $804.5K in option awards, accounting for 56% of the total pay in 2020.
Gergen also received $194.7K in non-equity incentive plan, $432.7K in salary and $9.1K in other compensation.
Rankings
In 2020, Mark J. Gergen's compensation ranked 7,001st out of 13,090 executives tracked by ExecPay. In other words, Gergen earned more than 46.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,001 out of 13,090 | 47th |
Division Manufacturing | 2,922 out of 5,620 | 48th |
Major group Chemicals And Allied Products | 1,181 out of 2,253 | 48th |
Industry group Drugs | 1,015 out of 1,953 | 48th |
Industry Biological Products, Except Diagnostic Substances | 244 out of 411 | 41st |
Source: SEC filing on April 27, 2022.
Gergen's colleagues
We found two more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2020.